New NPS MedicineWise CEO announced
Monday, 06 September, 2021
has appointed Katherine Burchfield as Chief Executive Officer, starting 18 October 2021.
Burchfield is currently the Executive Director of Strategy, Services and Innovation, at Royal Far West (RFW). Over the past six years, she has led significant growth and innovation across RFW鈥檚 multidisciplinary health and disability services, including establishing Australia鈥檚 largest paediatric allied health telecare program.
Prior to joining RFW, Burchfield was Director of the Integrated Care Branch at the NSW Ministry of Health, leading a large policy portfolio including integrated care reforms, aged care, primary and community care, palliative care and disability. She also led the national health policy and research program for the Audit Commission in England and has consulted on multiple international health reform projects.
Dr Andrew Knight, Chair of NPS MedicineWise, said, 鈥淣PS MedicineWise has a critical role to play as steward of the quality use of medicines, bringing together healthcare consumers and stakeholders across the sector to make a meaningful difference in an increasingly dynamic healthcare landscape.
鈥淜atherine has a strong track record in leading complex portfolios and multidisciplinary teams. She enjoys bringing consumer and clinical perspectives together with evidence and commercial acumen, and creating positive work cultures that engage staff and deliver results. She is passionate about improving health systems and addressing health inequalities聽鈥 and has a particular interest in the effective use of information and incentives to support better decisions across the health sector.鈥
WA's Health Support Services appoints Giles Nunis CEO
In WA, Health Support Services has appointed Giles Nunis its new Chief Executive Officer,...
The ACCC institutes Federal Court proceedings against Bupa
The ACCC has instituted Federal Court proceedings against Bupa for breaches of the Australian...
Whiteley opens $25m Human Therapeutics Plant in the Hunter
Human Therapeutics Plant, a new $25 million facility for the manufacture of alcohol-based hand...